10-K: BioAtla Reports 2024 Results, Highlights Clinical Progress and Financial Outlook

BioAtla, a clinical-stage biopharmaceutical company, provides an update on its 2024 financial results and ongoing clinical development programs focused on conditionally active biologics (CABs) for solid tumor cancers.

Summary

• BioAtla is a clinical-stage biopharmaceutical company focused on developing CAB therapies for solid tumor cancers.
• The company's CAB technology targets the tumor microenvironment to selectively bind to cancer cells while minimizing toxicity to healthy tissues.
• BioAtla's lead product candidates include mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), evalstotug (BA3071), and BA3182.
• In September 2024, BioAtla entered into a license agreement with Context Therapeutics for BA3362, a Nectin-4 x CD3 T cell engaging bispecific antibody, receiving an upfront payment and potential future milestones and royalties.
• As of December 31, 2024, BioAtla had approximately $49.0 million in cash and cash equivalents.
• The company anticipates that its current cash and cash equivalents will fund operations into the first half of 2026.
• BioAtla reported net losses of $69.8 million for 2024 and $123.5 million for 2023.
• The company is subject to ongoing regulatory obligations and review, even if its product candidates receive regulatory approval.
• BioAtla is subject to risks associated with conducting business internationally, including in China.
• In March 2025, BioAtla announced a workforce reduction of approximately 30% to manage resources.
• The company's stock is currently not in compliance with Nasdaq's continued listing requirements.
• BioAtla's auditor included an explanatory paragraph in its report regarding the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as the Context Therapeutics licensing agreement and ongoing clinical trials, the company's financial losses, going concern uncertainty, and Nasdaq compliance issues weigh heavily on the overall sentiment.

Positives

• The company is advancing clinical-stage CAB programs.
• The licensing agreement with Context Therapeutics provides upfront revenue and potential future milestones and royalties.
• The company has cash and cash equivalents to fund operations into the first half of 2026.

Negatives

• The company has a history of significant losses and expects to continue to incur losses for the foreseeable future.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company's stock is currently not in compliance with Nasdaq's continued listing requirements.
• A workforce reduction of approximately 30% was announced in March 2025.

Risks

• The company's product candidates may fail in development or suffer delays.
• The company is substantially dependent on the success of its patented CAB technology platform.
• The company faces competition from entities that have developed or may develop product candidates for cancer.
• The company may be unable to obtain U.S. or foreign regulatory approval for its product candidates.
• The company may not realize the anticipated benefits of its workforce reductions.
• The company may be unable to establish sales, marketing, and distribution capabilities.
• A portion of the company's research and development activities take place in China, which is subject to various risks.
• The company faces risks related to health epidemics and outbreaks.
• The company may be unable to obtain, maintain, and protect its intellectual property rights.
• The company's principal stockholders and management own a significant percentage of its stock and will be able to exert significant control over matters subject to stockholder approval.

Future Outlook

BioAtla expects to continue to incur significant operating expenses for the foreseeable future due to the cost of research and development, including conducting clinical trials and the regulatory approval process for its product candidates. The company anticipates that its current cash and cash equivalents will fund operations into the first half of 2026.

Industry Context

The biotechnology and biopharmaceutical industries, including the oncology subsector, are characterized by rapid evolution of technologies, competition and strong defense of intellectual property. BioAtla faces competition from a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions.

Comparison to Industry Standards

• The document does not contain specific details to make a detailed comparison to industry standards.
• The document does not contain specific details to make a detailed comparison to global benchmarks.
• The document does not contain specific details to make a detailed comparison to comparible companies.
• The document does not contain specific details to make a detailed comparison to projects.
• The document does not contain specific details to make a detailed comparison to results.

Related Party Transactions

• The company has entered into certain related party transactions with Himalaya Therapeutics SEZC, Inversagen, LLC and BioAtla Holdings, LLC, including various licensing arrangements with respect to certain CAB antibodies.
• Dr. Short and his spouse are each a manager of Inversagen, LLC and BioAtla Holdings, LLC and a director of Himalaya Therapeutics SEZC.
• Dr. Shorts spouse is also an officer of Himalaya Therapeutics SEZC.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and uncertainty regarding the company's ability to continue as a going concern.
• Employees are affected by the workforce reduction of approximately 30%.
• Customers (potential patients) may benefit from the continued development of novel cancer therapies.
• Suppliers and creditors face potential risks related to the company's financial stability.

Next Steps

• Continue clinical trials for mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182.
• Seek partnering opportunities across the portfolio, including for clinical-stage programs.
• Monitor the bid price of the Company's listed securities and may, if appropriate, consider available options to regain compliance with the Rule.

Key Dates

Keywords

BioAtla, CAB, Mecbotamab Vedotin, Ozuriftamab Vedotin, Evalstotug, BA3182, Clinical Trials, Biopharmaceutical, Oncology, Antibody-Drug Conjugates, Financial Results, Context Therapeutics, License Agreement, Nasdaq, Going Concern